Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.

The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors.

The gut microbiome has emerged as a potential factor in cancer pathogenesis, but its role in non-functioning pituitary neuroendocrine tumors (NF-PitNETs) remains unclear. This study aimed to elucidate ...

Jennifer Chan, MD, MPH, discussed the findings from the phase 3 CABINET trial leading to the FDA approval of cabozantinib in patients with neuroendocrine tumors.

Carcinoid syndrome is a rare condition typically affecting people with advanced carcinoid tumors. These rare, slow-growing tumors affect hormone-releasing neuroendocrine cells. The tumors can develop ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

The FDA has ap­proved Ex­elix­is’ can­cer drug Cabome­tyx to treat ad­vanced neu­roen­docrine tu­mors in­side and out­side of the pan­creas, mark­ing two new in­di­ca­tions for ...